DE3687541D1 - Verwendung von kalziumantagonisten zur anfertigung von zusammensetzungen fuer entziehungssymptome. - Google Patents

Verwendung von kalziumantagonisten zur anfertigung von zusammensetzungen fuer entziehungssymptome.

Info

Publication number
DE3687541D1
DE3687541D1 DE8686106111T DE3687541T DE3687541D1 DE 3687541 D1 DE3687541 D1 DE 3687541D1 DE 8686106111 T DE8686106111 T DE 8686106111T DE 3687541 T DE3687541 T DE 3687541T DE 3687541 D1 DE3687541 D1 DE 3687541D1
Authority
DE
Germany
Prior art keywords
compositions
production
withdrawal symptoms
calcium antagonists
opioid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8686106111T
Other languages
English (en)
Other versions
DE3687541T2 (de
Inventor
Esam E El-Fakahany
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc filed Critical Miles Inc
Publication of DE3687541D1 publication Critical patent/DE3687541D1/de
Application granted granted Critical
Publication of DE3687541T2 publication Critical patent/DE3687541T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DE8686106111T 1985-05-13 1986-05-05 Verwendung von kalziumantagonisten zur anfertigung von zusammensetzungen fuer entziehungssymptome. Expired - Fee Related DE3687541T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73366485A 1985-05-13 1985-05-13

Publications (2)

Publication Number Publication Date
DE3687541D1 true DE3687541D1 (de) 1993-03-04
DE3687541T2 DE3687541T2 (de) 1993-05-13

Family

ID=24948609

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686106111T Expired - Fee Related DE3687541T2 (de) 1985-05-13 1986-05-05 Verwendung von kalziumantagonisten zur anfertigung von zusammensetzungen fuer entziehungssymptome.

Country Status (6)

Country Link
US (1) US4797410A (de)
EP (1) EP0204951B1 (de)
JP (1) JPS61260025A (de)
AT (1) ATE84713T1 (de)
CA (1) CA1275928C (de)
DE (1) DE3687541T2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3806277A1 (de) * 1988-02-27 1989-09-07 Troponwerke Gmbh & Co Kg Verwendung von 1,4-dihydropyridin-derivaten
WO1990011074A1 (en) * 1989-03-22 1990-10-04 Pang Peter K T Parathyroid hypertensive factor
US5886012A (en) * 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
CA2016465A1 (en) * 1989-06-02 1990-12-02 Zola Phillip Horovitz Method for preventing or treating anxiety employing a calcium channel blocker
US5124340A (en) * 1989-06-28 1992-06-23 The United States Of America As Represented By The Department Of Health And Human Services Use of calcium channel blocker to prevent cocaine induced craving and reinforcement
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US6159501A (en) * 1996-03-08 2000-12-12 Nycomed Danmark A/S Modified release multiple-units dosage composition for release of opioid compounds
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
KR101216270B1 (ko) 1999-10-29 2012-12-31 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
GB0019055D0 (en) * 2000-08-03 2000-09-27 Unilever Plc Antiperspirant and deodorant products and methods for their use
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
WO2008011595A2 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system
US20170071879A1 (en) * 2015-09-15 2017-03-16 Alexandre Vamvakides Prototypical analgesic profile of 3,3-diphenyl-n-(1-phenylethyl)propan-1-amine (fendiline)
GR1009145B (el) * 2016-08-10 2017-10-20 Αλεξανδρος Δημητριου Βαμβακιδης Πρωτοτυπη αναλγητικη δραση της 3,3-διφαινυλο-ν-(1-φαινυλαιθυλ) προπαν-1-αμινη (fendiline)

Also Published As

Publication number Publication date
JPH0584287B2 (de) 1993-12-01
US4797410A (en) 1989-01-10
JPS61260025A (ja) 1986-11-18
EP0204951A3 (en) 1990-05-30
EP0204951B1 (de) 1993-01-20
DE3687541T2 (de) 1993-05-13
EP0204951A2 (de) 1986-12-17
CA1275928C (en) 1990-11-06
ATE84713T1 (de) 1993-02-15

Similar Documents

Publication Publication Date Title
DE3687541T2 (de) Verwendung von kalziumantagonisten zur anfertigung von zusammensetzungen fuer entziehungssymptome.
DE3588190T2 (de) Vorrichtung zur transdermalen Applikation von Medikamenten
LT2063B (lt) Guanino dariniu arba ju farmaceutiskai tinkamu drusku gavimo budas
EG18081A (en) Combination of angiotensin-converting enzyme inhibitors with calcium antagonists as well as the use indurugs
DE3671165D1 (de) Orthopaedische schiene.
ATA272785A (de) Implantierbare vorrichtung zur dosierten abgabe von insulin oder anderen langzeitmedikamenten
DE3667605D1 (de) Windel zur verhuetung von wundliegen.
DK49488D0 (da) Anaestesi-praeparat
KR890701124A (ko) 피브린 침착 또는 유착을 방지하기 위한 방법 및 치료 조성물
DK445985D0 (da) Implanterbar insulintilfoeringsindretning
EP0204129A3 (de) Verwendung von Kalziumantagonisten zur Anfertigung von Zusammensetzungen für die rekonstruktive Chirurgie
DE3485580D1 (de) Algorithmus zur verabreichung von insulin.
FI860226A0 (fi) Spiralelementband med skyddade kanter.
DE8817175U1 (de) Endotrachealkanüle
IT8520234A0 (it) Composizione farmaceutiche adattivita' dopominergica.
DE68906167T2 (de) Zusammensetzung zur erkennung von paradontalen krankheiten.
DE3584267D1 (de) Vorrichtung zur sicherung der lage der zungenschienen von gleisweichen.
DK623984D0 (da) Farmaceutisk doseringsenhed
DE3685404D1 (de) Bahnenzufuehrvorrichtung.
DK453785D0 (da) Laegemiddel med grf-virkning
FI860225A0 (fi) Banformningsvira med foerstaerkta kanter.
IT1237087B (it) N,n'-di-(trimetossibenzoil) piperazine 2-metossicarbonil sostituite, procedimento per preparare le stesse e composti terapeutici che le contengono.
ATA227186A (de) Schwellenschuh zur elastischen lagerung von schwellen
IT8220251A0 (it) Composizione farmaceutica adattivita' immunomodulatrice.
DE68905343T2 (de) Dosisform zur verabreichung von calciumantagonisten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee